Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Genome Biologics logo — Genome Biologics develops RNAi therapies for cardiovascular...

Genome Biologics

Genome Biologics develops RNAi therapies for cardiovascular and cardiometabolic disease, targeting specific tissue.

Founded 2017

General Information

Company Name Genome Biologics
Founded Year 2017
Social

Get notified when Genome Biologics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Genome Biologics

Genome Biologics is a biotech startup founded in 2017 with a mission to develop innovative RNA interference (RNAi) therapies for cardiovascular and cardiometabolic diseases. They have pioneered cutting-edge RNAi interventions tailored for specific tissues to target the transcriptome of these diseases, addressing a vital need in the medical field. Their state-of-the-art technology platforms allow for the expedited creation of RNAi therapies, offering promising solutions where current treatments are ineffective or absent. Genome Biologics presents an exciting opportunity for venture capitalists seeking to invest in the forefront of biotechnology and medical innovation.

Taxonomy: RNAi therapies, Cardiovascular disease, Cardiometabolic disease, Transcriptome targeting, Tissue-specific treatments, RNA interference, Therapeutic innovation

No funding data available for Genome Biologics yet.

Get notified when Genome Biologics raises funding

Genome Biologics Alternatives & Competitors

Genome Biologics vs
Corsera Health
Corsera Health

Extending Healthspan by Predicting and Preventing Cardiovascular Disease

Series A
15 employees
Biotechnology, Pharmaceutical
Genome Biologics vs
Tangram Therapeutics
Tangram Therapeutics United Kingdom

Relentless medicine discovery.

Series Unknown
42 employees
Biotechnology, Health Care
Genome Biologics vs
TAmiRNA GmbH
TAmiRNA GmbH Austria

stability for life

Grant
14 employees
Biotechnology, Health Care

FAQ About Genome Biologics

Genome Biologics develops RNAi therapies for cardiovascular and cardiometabolic disease, targeting specific tissue.
Genome Biologics was founded in 2017.
Top alternatives and competitors to Genome Biologics include Corsera Health, Tangram Therapeutics, TAmiRNA GmbH, Switch Therapeutics, Phio Pharmaceuticals Corp.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genome Biologics and Corsera Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Genome Biologics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy